Back to results
US 12,491,245 B2Granted
Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
AssigneesContrafect Corporation, Trellis Bioscience, LLC
InventorsAngeles Estelles, Lawrence M. Kauvar, Adam Vigil, Michael Wittekind
Life of this patent
Estimating the term…
Abstract
Antibodies, compositions and methods are provided for treatment and prophylaxis of influenza virus. Antibodies and antigen-binding fragments are provided that bind near the HA0 maturation cleavage site consensus sequence of influenza hemagglutinin A. Antibody compositions, combinations and methods for effective passive immunization across influenza A and B strains are also provided.
Claims23
A pharmaceutical composition formulated for intranasal or inhalation administration and effective for treatment or prophylaxis of influenza viral infection in a subject comprising:
- (a) a first antibody or antigen-binding fragment thereof that binds to and/or inhibits influenza virus comprising:
- a heavy chain amino acid sequence comprising a heavy chain variable region (HCVR) comprising a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence of SEQ ID NO:
- 11, a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence of SEQ ID NO:
- 12 and a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence of SEQ ID NO:13 and
- a light chain amino acid sequence comprising a light chain variable region (LCVR) comprising a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence of SEQ ID NO:
- 14, a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence of SEQ ID NO:
- 15, and a light chain complementarity determining region 3 (LCDR3) comprising the amino acid sequence of SEQ ID NO:
- 16;
- (b) a second antibody or antigen-binding fragment thereof that binds to and/or inhibits influenza virus comprising:
- a heavy chain amino acid sequence comprising HCVR comprising a HCDR1 comprising the amino acid sequence of SEQ ID NO:
- 21, a HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 22, and a HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 23 and a light chain amino acid sequence comprising a LCVR comprising a LCDR1 comprising the amino acid sequence of SEQ ID NO:
- 24, a LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 25, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 26;
- and
- (c) a third antibody or antigen-binding fragment thereof that binds to one or more strains of each of influenza B Yamagata and influenza B Victoria clades comprising:
- a heavy chain amino acid sequence comprising a HCVR comprising:
- a heavy chain amino acid sequence comprising a HCVR comprising:
- a HCDR1 comprising the amino acid sequence of SEQ ID NO:241, a HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 242, and a HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 243 and a light chain amino acid sequence comprising a LCVR comprising:
- a LCDR1 comprising the amino acid sequence of SEQ ID NO:
- 244, a LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 245, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 246.
24 more elements
A method for the treatment or prophylaxis of influenza infection in a subject which method comprises administering intranasally (IN) or via inhalation to a subject a pharmaceutical composition comprising:
- (a) a first antibody or antigen-binding fragment thereof that binds to and/or inhibits influenza virus comprising:
- a heavy chain amino acid sequence comprising a heavy chain variable region (HCVR) comprising a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence of SEQ ID NO:
- 11, a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence of SEQ ID NO:
- 12 and a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence of SEQ ID NO:13 and a light chain amino acid sequence comprising a light chain variable region (LCVR) comprising a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence of SEQ ID NO:
- 14, a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence of SEQ ID NO:
- 15, and a light chain complementarity determining region 3 (LCDR3) comprising the amino acid sequence of SEQ ID NO:
- 16;
- (b) a second antibody or antigen-binding fragment thereof that binds to and/or inhibits influenza virus comprising:
- a heavy chain amino acid sequence comprising HCVR comprising a HCDR1 comprising the amino acid sequence of SEQ ID NO:
- 21, a HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 22, and a HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 23 and a light chain amino acid sequence comprising a LCVR comprising a LCDR1 comprising the amino acid sequence of SEQ ID NO:
- 24, a LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 25, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 26;
- and
- (c) a third antibody or antigen-binding fragment thereof that binds to one or more strains of each of influenza B Yamagata and influenza B Victoria clades comprising:
- a heavy chain amino acid sequence comprising a HCVR comprising:
- a heavy chain amino acid sequence comprising a HCVR comprising:
- a HCDR1 comprising the amino acid sequence of SEQ ID NO:241, a HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 242, and a HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 243 and a light chain amino acid sequence comprising a LCVR comprising:
- a LCDR1 comprising the amino acid sequence of SEQ ID NO:
- 244, a LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 245, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 246.
23 more elements
Dependencies are inferred from the claim text.